ESH Day 3

Digital and Pharmacologic Innovations in Diabetes

by Prateek Chopra | June 15, 2026 | Cardiology Conferences | ESH 2026 Unmet Cardiometabolic Need: Address the broader cardiometabolic burden in type 2 diabetes (T2DM), where ~75% of patients have concomitant hypertension and a 2–4× elevated cardiovascular (CV) risk. Treatment goals extend beyond glycemic control to include cardiovascular and renal protection, facilitated by digital health technologies and novel pharmacotherapies. Digital

Digital and Pharmacologic Innovations in Diabetes Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

A Fixed-Dose Triple-Combination Therapy for the Initial Steps of Hypertension Treatment: Protocol for the NEXT RandomizedClinical Trial

by Prateek Chopra | June 15, 2026 | Cardiology Conferences | ESH 2026 Research Objective: Evaluate whether low-to-moderate-dose fixed-dose triple therapy improves peripheral and central blood pressure, arterial stiffness, and endothelial function compared with moderate-to-high-dose dual therapy in patients with uncontrolled hypertension. Study Design: Patient Population and Baseline Characteristics: Key Features and Rationale: The NEXT Trial is designed to determine whether

A Fixed-Dose Triple-Combination Therapy for the Initial Steps of Hypertension Treatment: Protocol for the NEXT RandomizedClinical Trial Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

Frequency and Predictive Factors of White-Coat Hypertension in Grade 1 Hypertensive Patients: Results of the Hungarian ABPM Registry

by Prateek Chopra | June 14, 2026 | Cardiology Conferences | ESH 2026 Study Focus: Assess the prevalence of white-coat hypertension (WCH) in patients with grade 1 hypertension (gr. 1 HT) and identify predictive factors distinguishing WCH from sustained hypertension. Study Design: Key Findings: Clinical Implications: WCH affects a substantial proportion of patients with grade 1 hypertension, particularly among women, older

Frequency and Predictive Factors of White-Coat Hypertension in Grade 1 Hypertensive Patients: Results of the Hungarian ABPM Registry Read Post »

Leave a Comment / ESH Day 3 / / / , , ,

Uric Acid as an Additional Component of Metabolic Syndrome –Its Association with Hypertension-Mediated Organ Damage

by Prateek Chopra | June 14, 2026 | Cardiology Conferences | ESH 2026 Unmet Pediatric Hypertension Risk: Metabolic syndrome (MS) is associated with hypertension-mediated organ damage (HMOD) in children, but the predictive value of different MS definitions and the role of serum uric acid remain uncertain. This study evaluated how MS definitions and uric acid levels contribute to early cardiovascular risk

Uric Acid as an Additional Component of Metabolic Syndrome –Its Association with Hypertension-Mediated Organ Damage Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

Managing the Complex Hypertensive Patients in a Multi-Morbid World

by Prateek Chopra | June 14, 2026 | Cardiology Conferences | ESH 2026 Research Objective: Examine the epidemiological burden of multimorbidity in hypertension, the interplay between HTN and common comorbidities, and evidence-based strategies for cardiovascular risk reduction in complex hypertensive patients. Study Context: Evidence and Data Sources: Patient Profile and Key Findings: Management requires individualized, goal-directed therapy focused on reducing cardiovascular

Managing the Complex Hypertensive Patients in a Multi-Morbid World Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

EASO Framework for the Pharmacological Treatment of Obesity

by Prateek Chopra | June 12, 2026 | Cardiology Conferences | ESH 2026 Personalized Obesity Care: Obesity is a chronic, relapsing adiposity-based disease leading to mechanical and metabolic complications via complex genetic, biological, and environmental interactions. Effective management requires a patient-centered approach combining lifestyle interventions, nutrition, physical activity, pharmacotherapy, and bariatric surgery when appropriate. Evidence-Based Framework: Treatment Principles: Key Insights &

EASO Framework for the Pharmacological Treatment of Obesity Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

Beta-Blockers in Patients with Hypertension and Cardiovascular Disease: When to Start and When to Continue

by Prateek Chopra | June 13, 2026 | Cardiology Conferences | ESH 2026 Personalized Obesity Care: Obesity is a chronic, relapsing adiposity-based disease leading to mechanical and metabolic complications via complex genetic, biological, and environmental interactions. Effective management requires a patient-centered approach combining lifestyle interventions, nutrition, physical activity, pharmacotherapy, and bariatric surgery when appropriate. Evidence-Based Framework: Treatment Principles: Key Insights &

Beta-Blockers in Patients with Hypertension and Cardiovascular Disease: When to Start and When to Continue Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

Immunization and Cardiovascular Protection: Evidence andFuture Directions

by Prateek Chopra | June 12, 2026 | Cardiology Conferences | ESH 2026 Clinical Rationale: Growing evidence supports a bidirectional relationship between infections and cardiovascular disease (CVD). Respiratory infections can trigger acute cardiovascular events and exacerbate pre-existing conditions, while patients with underlying CVD are at higher risk of severe infectious outcomes. Influenza infection, for example, increases the incidence of acute myocardial

Immunization and Cardiovascular Protection: Evidence andFuture Directions Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

The SATELLITE Trial: The Hidden Dimension of Hypertension Control

by Prateek Chopra | June 11, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Objective: Evaluate the effects of telmisartan/amlodipine (T/A) and telmisartan/amlodipine/hydrochlorothiazide (T/A/HCTZ) SPCs on 24-hour blood pressure (BP), average real variability (ARV), and office BP control. Study Design: Baseline Characteristics: Key Findings: ARV Improvements: Clinical Implications: SATELLITE confirms that SPC therapy effectively reduces both BP and variability, highlighting additional

The SATELLITE Trial: The Hidden Dimension of Hypertension Control Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,

The INDependent Study: First Real-World Clinical Experience with an ARB/Indapamide Single-Pill Combination

by Prateek Chopra | June 11, 2026 | Cardiology Conferences | ESH 2026 Study Focus: Evaluate the real-world effectiveness, metabolic safety, and tolerability of valsartan/indapamide single-pill combinations (SPCs) in European hypertensive patients in routine clinical practice. Study Design: Patient Population: Key Findings: The INDependent study provides the first real-world evidence that valsartan/indapamide SPC delivers marked, sustained, and well-tolerated BP control in

The INDependent Study: First Real-World Clinical Experience with an ARB/Indapamide Single-Pill Combination Read Post »

Leave a Comment / ESH Day 3 / / / , , , ,
Scroll to Top